Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
A peer-reviewed study published in JMIR mHealth and uHealth found that Brook.ai’s AI-supported continuous care model improved hypertension control by 26 percent compared to traditional remote patient monitoring.
Courier Health has raised $50 million in Series B funding led by Oak HC/FT, with participation from Norwest and Work-Bench, to enhance its AI-powered patient experience platform for the life sciences industry.
Ada Health and CUF conducted a real-world study published in NEJM AI showing that three in five patients changed their care decisions after using Ada’s symptom assessment tool, doubling the rate of clinically appropriate care.
Amperos Health has raised $16 million in Series A funding led by Bessemer Venture Partners as it launches its AI platform for automating healthcare claim denial management and revenue recovery.
Shapiro+Raj has introduced Stella.ai, an AI agent designed for life sciences marketing and insights, and appointed Scott Swigart as Chief Product Officer and Amir Kapadia as President to lead its growth.
The Catalight Group and Cognoa have formed a partnership connecting Cognoa's FDA authorized Canvas Dx diagnostic tool with Catalight's national behavioral health network to accelerate autism diagnosis and treatment access.
GRAIL will present new data from the NHS-Galleri trial and PATHFINDER 2 study evaluating its Galleri multi-cancer early detection test at the 2026 ASCO Annual Meeting in Chicago.
OpenProtein.AI, founded by MIT alumni Tristan Bepler and Tim Lu, has launched a no-code platform that enables researchers to design and analyze proteins using AI foundation models. The platform, which includes the PoET protein language model, is available to pharmaceutical companies and academic scientists worldwide.
Viva Biotech discussed the integration of AI and flow chemistry in drug discovery during its recent webinar, showcasing advances in automated synthesis and scalable reaction workflows.
Castle Biosciences announced it will present new data showing that its DecisionDx-Melanoma test can identify early-stage melanoma patients at greater risk of recurrence and poor outcomes. The findings will be shared at the European Congress of Dermato-Oncology and the American College of Mohs Surgery meetings.
VytlOne has launched VytlAIQ, an AI-powered platform designed to unify data, automate workflows, and provide predictive intelligence for 340B and specialty pharmacy operations.
Brado AI has completed the Centers for Medicare & Medicaid Services Health Technology Ecosystem pledge, advancing interoperability and patient-centered care through its Conversational Engagement Platform.
WCG has announced its acquisition of The Contract Network, integrating its AI technology into the ClinSphere platform to enhance contract and study start-up workflows across clinical research operations.
BayCare Health System and robotics startup Rovex have launched a pilot at Morton Plant Hospital in Clearwater, Florida, to test robotic support for hospital operations and patient transport workflows. The initial phase will study transport patterns and workflow efficiency, with no patient transport planned at this stage.
MasterControl has launched Event Summarizer, an AI feature within its Quality Excellence solution that creates instant summaries of complex quality events to speed decision-making in life sciences operations.
MyOme has appointed Sam Roosz and Dr. Ravi Thadhani to its Board of Directors, bringing expertise in healthcare technology, clinical operations, and regulatory strategy to support its AI powered whole genome healthcare platform.
Accuity has been named a winner in the Health category of the 2026 Artificial Intelligence Excellence Awards by the Business Intelligence Group for its physician-governed AI platform used in hospital revenue integrity and clinical documentation.
Insilico Medicine has announced the creation of the industry's first Longevity Board to provide scientific oversight and strategic direction for AI-based aging and drug discovery research. The board will be chaired by Andrew Adams of Eli Lilly and Company.
Rad AI published a peer-reviewed study showing that radiology-specific AI models better meet radiologist expectations than general-purpose large language models when generating clinical impressions.
CerraCap Ventures has invested in Nephronomics, an AI bio precision medicine company developing data driven approaches to kidney disease research and drug discovery. The partnership aims to advance precision therapies using one of the largest renal datasets in the world.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.